LGNDZ LIGAND PHARMACEUTICALS INC: institutional ownership and insider trading
1 funds reported holding $16 of LIGAND PHARMACEUTICALS INC in their latest 13F filings; in Q2 2026 funds net bought $0, with 0 new positions and 0 funds selling out; over the last 12 months insiders bought $0 and sold $34.7M on the open market; over its last four quarters it reported revenue of $291M and net income of $197M.
LGNDZ revenue and earnings
- Quarter ended Jun 30, 2026: revenue $63.7M, net income $48.5M, EPS 2.22
- Quarter ended Mar 31, 2026: revenue $51.7M, net income −$13.3M, EPS -0.67
- Quarter ended Dec 31, 2025: revenue $59.7M, net income $44.8M, EPS 2.42
- Quarter ended Sep 30, 2025: revenue $115M, net income $117M, EPS 5.68
Largest institutional holders of LGNDZ
- Ancora Advisors LLC — $16
Recent LGNDZ insider trades
- Oct 2, 2026: Reardon Andrew sold 5,000 shares ($1.52M)
- Sep 10, 2026: Zimmermann Martine sold 1,200 shares ($342K)
- Sep 3, 2026: Reardon Andrew sold 5,000 shares ($1.43M)
- Aug 12, 2026: Haas Jason sold 7,138 shares ($2.09M)
5%+ owners
- BlackRock, Inc.: 14.5% (Schedule 13G/A, filed Oct 17, 2025)
- Invesco Ltd.: 6.1% (Schedule 13G, filed Aug 13, 2026)
- Vanguard Portfolio Management: 5.6% (Schedule 13G, filed May 1, 2026)
- JANUS HENDERSON GROUP PLC: 5.3% (Schedule 13G/A, filed Nov 14, 2025)
- Vanguard Capital Management: 5.0% (Schedule 13G, filed May 1, 2026)
Who owns the most LGNDZ stock?
The largest institutional holders of LIGAND PHARMACEUTICALS INC in the latest 13F filings are Ancora Advisors LLC ($16).
Are insiders buying or selling LGNDZ?
Over the last 12 months insiders bought $0 and sold $34.7M of LIGAND PHARMACEUTICALS INC stock on the open market (SEC Form 4).
What was LGNDZ's revenue last quarter?
LIGAND PHARMACEUTICALS INC reported revenue of $63.7M for the quarter ended June 30, 2026, with net income of $48.5M.